APLN and melanoma: As further proof-of-principle, MM54 attenuates the pro-tumourigenic effects of apelin in a mouse melanoma lung metastasis model (Berta et al., 2021), suggesting that apelin receptor blocking therapy is not necessarily limited to brain cancers.